Clinical Trials Browser

Terminated × Recurrence × pembrolizumab × Clear all

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Phase 2 Terminated

4 enrolled 8 charts

Gynecologic

Recurrence, Endometrial Neoplasms

NCT04478695 2024-03-08

Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

1 enrolled 2 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03257722 2024-02-28

PIL

Phase 1/2 Terminated

4 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT05357898 2024-02-23

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

20 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase 1 Terminated

6 enrolled 19 charts

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT02963610 2021-12-30

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Phase 1/2 Terminated

3 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02289222 2019-11-05

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

48 enrolled 10 charts

Plasma cell

Multiple Myeloma, Recurrence

Clinical Trials

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

PIL

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma